

GLAXOSMITHKLINE PLC

Form 6-K

October 14, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 14 October 2016

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes ☐ No ☒

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Sir Andrew Witty
  - b) Position/status Chief Executive Officer
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's ShareReward Plan.
  - c) Price(s) and volume(s)
 

| Price(s)                 | Volume(s) |
|--------------------------|-----------|
| £17.0491                 | 38        |
| n/a (single transaction) |           |
  - d) Aggregated information  
Aggregated volume Price
  - e) Date of the transaction 2016-10-13
  - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr R G Connor
  - b) Position/status President, Global Manufacturing & Supply
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
- 3.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

|    |                                         |                                                                                                                                                                         |           |
|----|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
|    |                                         | Ordinary shares of 25 pence each ('Ordinary Shares')                                                                                                                    |           |
| a) | Description of the financial instrument | ISIN: GB0009252882                                                                                                                                                      |           |
|    |                                         | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's ShareReward Plan. |           |
| b) | Nature of the transaction               |                                                                                                                                                                         |           |
| c) | Price(s) and volume(s)                  | Price(s)                                                                                                                                                                | Volume(s) |
|    |                                         | £17.0491                                                                                                                                                                | 47        |
|    |                                         | n/a (single transaction)                                                                                                                                                |           |
|    |                                         | Aggregated information                                                                                                                                                  |           |
| d) | Aggregated volume Price                 |                                                                                                                                                                         |           |
| e) | Date of the transaction                 | 2016-10-13                                                                                                                                                              |           |
| f) | Place of the transaction                | London Stock Exchange (XLON)                                                                                                                                            |           |

1. Details of PDMR/person closely associated with them ('PCA')

|    |                                 |                         |
|----|---------------------------------|-------------------------|
| a) | Name                            | Mr S Dingemans          |
| b) | Position/status                 | Chief Financial Officer |
| c) | Initial notification/ amendment | Initial notification    |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

|    |      |                      |
|----|------|----------------------|
| a) | Name | GlaxoSmithKline plc  |
| b) | LEI  | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

|    |                                         |                                                                                                    |  |
|----|-----------------------------------------|----------------------------------------------------------------------------------------------------|--|
|    |                                         | Ordinary shares of 25 pence each ('Ordinary Shares')                                               |  |
| a) | Description of the financial instrument | ISIN: GB0009252882                                                                                 |  |
|    |                                         | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 |  |
| b) | Nature of the transaction               |                                                                                                    |  |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

October 2016, on shares held  
through the Company's  
ShareReward Plan.

|    |                           |                      |                 |
|----|---------------------------|----------------------|-----------------|
| c) | Price(s) and<br>volume(s) | Price(s)<br>£17.0491 | Volume(s)<br>15 |
|----|---------------------------|----------------------|-----------------|

n/a (single transaction)

d) Aggregated information  
Aggregated volume Price

|    |                          |                                 |
|----|--------------------------|---------------------------------|
| e) | Date of the transaction  | 2016-10-13                      |
| f) | Place of the transaction | London Stock Exchange<br>(XLON) |

1. Details of PDMR/person closely associated with them ('PCA')

|    |                 |                                    |
|----|-----------------|------------------------------------|
| a) | Name            | Mr N Hirons                        |
| b) | Position/status | SVP, Global Ethics &<br>Compliance |

|    |                                    |                      |
|----|------------------------------------|----------------------|
| c) | Initial notification/<br>amendment | Initial notification |
|----|------------------------------------|----------------------|

2. Details of the issuer, emission allowance market participant, auction  
platform, auctioneer or auction monitor

|    |      |                      |
|----|------|----------------------|
| a) | Name | GlaxoSmithKline plc  |
| b) | LEI  | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of  
instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
place where transaction(s) has been conducted

|    |                                         |                                                                               |
|----|-----------------------------------------|-------------------------------------------------------------------------------|
| a) | Description of the financial instrument | Ordinary shares of 25 pence<br>each ('Ordinary Shares')<br>ISIN: GB0009252882 |
|----|-----------------------------------------|-------------------------------------------------------------------------------|

|    |                           |                                                                                                                                                                                           |
|----|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| b) | Nature of the transaction | Acquisition of Ordinary<br>Shares following the<br>re-investment of dividends<br>paid to shareholders on 13<br>October 2016, on shares held<br>through the Company's<br>ShareReward Plan. |
|----|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|    |                           |                      |                |
|----|---------------------------|----------------------|----------------|
| c) | Price(s) and<br>volume(s) | Price(s)<br>£17.0491 | Volume(s)<br>5 |
|----|---------------------------|----------------------|----------------|

|    |                        |                          |
|----|------------------------|--------------------------|
| d) | Aggregated information | n/a (single transaction) |
|----|------------------------|--------------------------|

Aggregated volume Price

e) Date of the transaction 2016-10-13  
 f) Place of the transaction London Stock Exchange  
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S A Hussain  
 b) Position/status President, Global  
 Pharmaceuticals

c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction  
 platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of  
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
 place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence  
 each ('Ordinary Shares')  
 ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary  
 Shares following the  
 re-investment of dividends  
 paid to shareholders on 13  
 October 2016, on shares held  
 through the Company's  
 ShareReward Plan.

c) Price(s) and Volume(s)  
 volume(s) £17.0491 9  
 n/a (single transaction)

d) Aggregated information  
 Aggregated volume Price

e) Date of the transaction 2016-10-13  
 f) Place of the transaction London Stock Exchange  
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D S Redfern  
 b) Position/status Chief Strategy Officer  
 c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument
 

Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

- b) Nature of the transaction
 

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's ShareReward Plan.

- c) Price(s) and volume(s)
 

|                          |           |
|--------------------------|-----------|
| Price(s)                 | Volume(s) |
| £17.0491                 | 53        |
| n/a (single transaction) |           |

- d) Aggregated information
 

Aggregated volume Price

- e) Date of the transaction 2016-10-13
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms C Thomas
  - b) Position/status SVP, Human Resources
  - c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument
 

Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

- b) Nature of the transaction
 

Acquisition of Ordinary Shares following the

re-investment of dividends  
paid to shareholders on 13  
October 2016, on shares held  
through the Company's  
ShareReward Plan.

|                              |                          |                 |
|------------------------------|--------------------------|-----------------|
| c) Price(s) and<br>volume(s) | Price(s)<br>£17.0491     | Volume(s)<br>53 |
|                              | n/a (single transaction) |                 |

d) Aggregated information  
Aggregated volume Price

|                             |                                 |
|-----------------------------|---------------------------------|
| e) Date of the transaction  | 2016-10-13                      |
| f) Place of the transaction | London Stock Exchange<br>(XLON) |

1. Details of PDMR/person closely associated with them ('PCA')

|                    |                                             |
|--------------------|---------------------------------------------|
| a) Name            | Mr P C Thomson                              |
| b) Position/status | SVP, Communications &<br>Government Affairs |

|                                       |                      |
|---------------------------------------|----------------------|
| c) Initial notification/<br>amendment | Initial notification |
|---------------------------------------|----------------------|

2. Details of the issuer, emission allowance market participant, auction  
platform, auctioneer or auction monitor

|         |                      |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc  |
| b) LEI  | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of  
instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
place where transaction(s) has been conducted

|                                            |                                                                               |
|--------------------------------------------|-------------------------------------------------------------------------------|
| a) Description of the financial instrument | Ordinary shares of 25 pence<br>each ('Ordinary Shares')<br>ISIN: GB0009252882 |
|--------------------------------------------|-------------------------------------------------------------------------------|

|                              |                                                                                                                                                                                           |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| b) Nature of the transaction | Acquisition of Ordinary<br>Shares following the<br>re-investment of dividends<br>paid to shareholders on 13<br>October 2016, on shares held<br>through the Company's<br>ShareReward Plan. |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                              |                          |                 |
|------------------------------|--------------------------|-----------------|
| c) Price(s) and<br>volume(s) | Price(s)<br>£17.0491     | Volume(s)<br>28 |
| d) Aggregated information    | n/a (single transaction) |                 |

Aggregated volume Price

e) Date of the transaction 2016-10-13  
 f) Place of the transaction London Stock Exchange  
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Dr P J T Vallance  
 b) Position/status President, Pharmaceuticals  
 R&D

c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction  
 platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of  
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
 place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence  
 each ('Ordinary Shares')  
 ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary  
 Shares following the  
 re-investment of dividends  
 paid to shareholders on 13  
 October 2016, on shares held  
 through the Company's  
 ShareReward Plan.

c) Price(s) and Volume(s)  
 volume(s) £17.0491 31  
 n/a (single transaction)

d) Aggregated information  
 Aggregated volume Price

e) Date of the transaction 2016-10-13  
 f) Place of the transaction London Stock Exchange  
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms E Walmsley  
 b) Position/status CEO Designate

- c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's ShareReward Plan.
- c) Price(s) and volume(s) Price(s) Volume(s)  
£17.0491 10  
n/a (single transaction)
- d) Aggregated information  
Aggregated volume Price
- e) Date of the transaction 2016-10-13
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mrs V A Whyte
- b) Position/status Company Secretary
- c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

|                                                      |                                                                                                                                                                         |                 |
|------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| b) Nature of the transaction                         | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's ShareReward Plan. |                 |
| c) Price(s) and volume(s)                            | Price(s)<br>£17.0491<br>n/a (single transaction)                                                                                                                        | Volume(s)<br>37 |
| d) Aggregated information<br>Aggregated volume Price |                                                                                                                                                                         |                 |
| e) Date of the transaction                           | 2016-10-13                                                                                                                                                              |                 |
| f) Place of the transaction                          | London Stock Exchange (XLON)                                                                                                                                            |                 |

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)  
Date: October 14, 2016

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc